In core binding factors (CBF) acute myeloid leukemia (AML), the disruption of CBFa/b genes impairs normal hematopoietic differentiation and is supposed to cooperate with additional mutations promoting proliferation. The incidence and the prognosis of receptor tyrosine kinase (RTK) c-Kit and FLT3 mutations and Ras mutations were evaluated in 103 pediatric and adult patients with CBF-AML. c-Kit mutations were present in 17% patients. c-Kit exon 8 mutations were more frequent in inv(16) than in t(8;21) subset (20 versus 6%). Only one patient had FLT3-ITD but FLT3-D835 was as frequent as reported in AML population (7%). Ras mutations were significantly more frequent in inv(16) than in t(8;21) subset (36 versus 8%, P ¼ 0.001). RTK mutations were associated with a higher white blood cell count (WBC) (36 versus 21 G/L, P ¼ 0.05). FLT3 mutations were significantly associated with a shorter EFS and survival (Po0.0001 and P ¼ 0.0002) owing to an excess of early events. c-Kit mutations were associated with a shorter EFS and RFS (P ¼ 0.002 and P ¼ 0.003) in t(8;21) but not inv(16) patients. As previously observed, Ras mutations did not affect prognosis. Screening for RTK mutations may help to identify patients with a more adverse outcome and thus susceptible to benefit from intensified protocols or RTK inhibitors. Leukemia (2006) 20, 965-970.
Introduction
The core binding factor (CBF) acute myeloid leukemia (AML) are defined by the presence of either t(8;21)(q22;q22) or inv(16)(p13;q22)/t(16;16)(p13;q22) chromosomal rearrangements that result in the disruption of CBF-a (AML1) and CBF-b genes encoding CBF subunits, respectively. Patients with CBF-AML account for about 15% of AML. Their median age is significantly lower and their prognosis better than patients with AML with normal karyotype or other chromosome aberrations. This favorable outcome with higher complete remission (CR) rate and lower incidence of relapse, [1] [2] [3] especially for patients receiving high-dose cytarabine in post-remission treatment, led several cooperative groups to discuss the indication of allogeneic stem cell transplantation (SCT) in CBF-AMLs. [4] [5] [6] The lack of benefit associated with allogeneic SCT in first CR in these patients has also been reported in large donor versus no-donor AML studies or overviews. [7] [8] [9] However, the outcome of patients with CBF-AML does not appear to be as homogeneous as their cytogenetic definition. Previous studies attempted to predict subgroups of CBF-AML patients associated with a worse prognosis. In both t(8;21) or inv(16)/t(16;16) subsets, the most widely recognized bad prognostic factor is a high initial white blood cell count (WBC). [4] [5] [6] A WBC index defined as the product of the WBC itself by the percentage of marrow blasts has been proposed for t (8;21) patients. 4 Besides WBC, the existence of additional cytogenetic abnormalities like the loss of the Y chromosome in t(8;21) male patients or trisomy 22 in inv (16) patients have also been related to modulate the outcome. 6 According to the model proposed by Gilliland et al., 10 AML may result from the association of class I mutations conferring a proliferative advantage to AML cells and class II mutations leading to impaired hematopoietic differentiation. In CBF-AML, AML1-ETO and CBFb-MYH11 gene fusions generated by t(8;21) or inv(16)/t(16;16) rearrangements represent these class II mutations, whereas activating mutations of c-Kit, FLT3, and Ras genes are good candidates for class I mutations. Actually, activating mutations of c-Kit and Ras genes have been reported with a particular high incidence in CBF-AML. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Of note, c-Kit mutations are roughly not observed in other AML subsets, at least in adults as a recent pediatric study reports a 6% incidence (7 out of 123 cases) in children with non-CBF AML. 17 Conversely, internal tandem duplication (ITD) of the FLT3 gene appeared to be quite rare in CBF-AML, as compared for instance to AML with a normal karyotype, even if FLT3-D835 point mutations may also be observed in this AML subset. Of great interest, it seems that mutations of these two c-Kit and FLT3 tyrosine kinase surface receptors (RTK) might be associated with higher WBC and a worse outcome in both CBF subsets. [13] [14] [15] In this study, we thus evaluated if the detection of c-Kit, FLT3, but also Ras mutations may be helpful to precise the outcome of patients with CBF-AML. This is of importance at a time when several specific RTK or Ras inhibitors are in clinical development.
Patients and methods

Patients and treatments
A total of 103 patients with de novo CBF-AML, treated in or according to previous or current adult ALFA (ALFA90, ALFA98) or pediatric LAME (LAME91, LAME99, ELAM02) trials (73 adults, 30 children) between 1990 and 2004 were retrospectively included in the present study. According to the Helsinki protocol, the patients or their guardians (above 18 years old) gave informed consent for the use of their samples for research studies. 9 /l (range, 2-257). High-dose cytarabine was given during consolidation courses in the ongoing ELAM02 and ALFA98 protocols in patients less than 50 years old and in the LAME99 protocol but not in previous ALFA90 and LAME91 trials. 21, 22 In total, 47% of patients received high-dose cytarabine during consolidation courses. The median follow-up was 4.4 years.
Detection of FLT3, c-Kit, N-Ras, and K-Ras mutations Gene mutations were detected on bone marrow or peripheral blood blast samples (median leukemic blast percentage, 59%). The presence of FLT3-ITD was analyzed by PCR on genomic DNA, using primer 11F and 12R, as previously reported. 23, 24 FLT3-ITDs were detected by abnormal longer PCR products. Cases displaying faint abnormal bands were confirmed after hybridization with an internal oligonucleotide probe, located on exon 12. To detect FLT3-D835, we used restriction fragment length polymorphism-mediated RT-PCR assays, as previously reported. 25 Amplified products were digested with EcoRV and resolved on an agarose gel. Undigested bands, indicative of FLT3-D835 mutation, were cut out for direct nucleotide sequencing to confirm the presence the mutation. Detection of c-Kit mutations was performed on genomic DNA by PCR fragment analysis and direct sequencing. To amplify the exon 8 of c-Kit, we used a fluorescently labeled forward primer 5 0 -(dyeD4)GCTGAGGTTTTCCAGCACTC-3 0 (Proligo, Boulder, CO, USA) and a reverse primer 5 0 -AATTGCAGTCCTT CCCCTCT-3 0 (Invitrogen, Cergy Pontoise, France). Fluorescent PCR products were subjected to capillary electrophoresis on denaturing polyacrylamide gel and analyzed by the CEQTM 8000 Genetic Analysis System (Beckman Coulter, Fullerton, CA, USA). The data were processed using Genetic Analysis System Software (Beckman Coulter). Samples from normal patients show one peak at 297 bp and patients with a del/ins of exon 8 presented two peaks. Abnormal profiles were confirmed by direct sequencing using the same non-fluorescent primers. To amplify the exon 17 of c-Kit, we used forward primer 5 0 -TGGTGTACTGAATACTTTAAAACAAAA-3 0 (Proligo, Boulder, CO, USA) and a reverse primer 5 0 -TGCAGGACTGTCAAGCA GAG-3 0 (Invitrogen, Cergy Pontoise, France). PCR products (294 bp) were both digested using Bsma1/Hinf1 restriction enzyme in order to detect D816 mutation and directly sequenced to detect adjacent mutations. After digestion two bands (143 and 151 bp) were observed in mutated cases and three bands (143, 72 and 79 bp) in non-mutated cases. Mutations affecting codons 12, 13 and 61 of N-Ras and K-Ras genes were analyzed, by direct sequencing of N-Ras or K-Ras genomic PCR products, as previously reported. 25 All direct sequencing was performed using ABIprism BigDye Terminators and AmpliTaq FS (Perkin Elmer, Foster City, CA, USA). Abnormal sequencing results were controlled by three separate experiments.
Statistical analysis
Patients characteristics and CR rates were compared using the Fisher's exact test for binary variables and the Mann-Whitney test for continuous variables. Relapse-free survival (RFS) and event-free survival (EFS), and overall survival (OS) were estimated by the Kaplan-Meier method and compared using the log-rank test.
Results
Incidence of RTK and Ras gene mutations in CBF-AML
Respective incidences of c-Kit, FLT3, and Ras gene mutations observed in the entire cohort of 103 CBF-AML patients studied are indicated in Table 1 Two patients presented both FLT3-D835 and c-Kit mutation (one exon8 and one D816 mutation). Overall, the incidence of RTK gene activating mutations was 20% without significant difference between inv(16)/t(16;16) and t(8;21) AML (26 versus 20%; P ¼ 0.48). Four patients with RTK gene mutation had also a Ras mutation. The global incidence of RTK and/or Ras mutation was 42%. This incidence was significantly higher in patients with inv(16)/t(16;16) AML than in those with t(8;21) AML (57 versus 28%; P ¼ 0.006).
Prognostic significance of RTK and Ras gene mutations in CBF-AML
Overall, the CR rate was 94%. As indicated in Table 2 , no gene mutation predicted a poor response to induction when compared to patients without mutation for that peculiar gene, except for FLT3. Among the eight FLT3-mutated cases, three did not achieve CR, one with t(8;21) and two with inv (16) . Even if numbers were very small, this difference was statistically significant (P ¼ 0.006 by the Fisher's exact test). All these three patients had FLT3-D835 mutation and failed because of refractory disease (two cases) or leukostasis-related acute respiratory failure (one case). Among the five other FLT3-mutated cases who achieved CR, two died in first CR (one allogeneic transplantation-related mortality and one meningeal hemorrhage before allogenic transplantation) and two relapsed, leading to significantly worse EFS and OS in each subgroup of CBF (Table 2 and Figure 1 ).
As shown in Table 2 , Ras mutations had no impact on CR rate, EFS or survival neither in patients with t(8;21) AML nor with inv(16)/t(16;16) AML. This was observed when Ras mutated cases were compared to all cases without Ras mutation, but also when FLT3-mutated cases were excluded from comparisons (not shown).
A similar lack of prognostic impact was observed when the 16 c-Kit mutated cases were compared to all cases without c-Kit mutation (Table 2 ) and also when FLT3-mutated cases were excluded from comparisons (not shown). Here, however, it appeared that the outcome of c-Kit mutated cases differed Figure 2 for OS.
Discussion
In the present study, we found a relatively low incidence of FLT3 activating mutations, a high incidence of Ras activating mutations, and an intermediate incidence of c-Kit activating mutations in a cohort of 103 patients with CBF-AML. In the twohit model proposed by Kelly and Gilliland, 10 AML may arise from the conjunction of a class II event altering normal hematopoietic differentiation and a class I event leading to decreased apoptosis and/or increased proliferative advantage in leukemic cells. Core binding factor AML, as well as t (15;17) promyelocytic leukemia, are considered as good examples for such two-event mechanisms. It could be thus considered as surprising to observe several class I events in the same single patient as it occurred in six patients of our study, except if one hypothesizes that an underlying genomic instability may explain the occurrence of these class I mutations.
The low 8% incidence of FLT3 mutations is in accordance with previous studies in CBF-AML patients even if the ITD/D835 ratio may vary from one study to another. 13, 14, 17 Larger reports evaluating these mutations in AML in general have already mentioned their low incidence in CBF-AML (for review, see reference Kottaridis et al. 26 ). Conversely to FLT3-ITD mostly reported to be associated with a shorter outcome, the prognostic value of FLT3-D835 mutations has been unclear. A metaanalysis by Yanada et al. 27 pointed out an adverse effect on disease-free survival of this mutation. On the contrary, the Medical Research Council reported recently a favorable prognosis associated with mutations of the FLT3 TK domain (Mead et al. Blood, 2005; 106: Abstract 334). The adverse prognostic value of FLT3 mutations we observe in this study seems contradictory to our previous publication reporting no prognostic significance of FLT3-ITD in AML. 23 However, both characteristics of the population and type of mutation considered differed between this studies. 23 Recently, Schnittger et al. 18 observed the same discrepancies concerning c-Kit D816 mutation that impacted the outcome of patients with t(8;21) AML but not of the entire large cohort screened.
As expected, we confirm in these CBF patients that Ras mutations are mostly observed in inv(16)/t(16;16) AML while very rarely in t(8;21) AML as well as their lack of prognostic significance. 11, 15 Of note, a high incidence of Ras mutation has been recently reported in childhood t(8;21) AML. 17 Reported incidences of c-Kit mutations in patients with CBF-AML are indicated in Table 3 . Mentioned studies are heterogeneous in terms of the number of patients studied, techniques used, and parts of the c-Kit gene, which have been screened. Both studies which reported higher incidences than the 17% observed here also screened the entire exon 17 as well as the JM domain of the gene (exons 10 and 11).
14-16 It appears, however, that our low 4% incidence of D816 mutation contrasts with the incidence reported by others. 13, 15, 20 This cannot be readily explained by technical considerations and could simply be due to the relatively small size of patient populations tested in all these studies. Ethnic and geographic variations may also be responsible for such disparities, as the most frequent c-Kit mutation in t(8;21) AML reported in the Chinese study by Wang et al. 16 involved N822 (10/54) and not D816 (9/54) amino acid. From a prognostic point of view, we confirm here the association between c-Kit mutations, higher WBC, and poor outcome at least for t(8;21) AML patients. 15, [18] [19] [20] However, we do not observe the worse outcome previously reported as associated with exon 8 mutations in inv(16)/t(16;16) AML patients. 13 The discrepancy of c-Kit mutations prognostic impact between t(8;21) and inv (16) was also reported by a recent Italian study. 20 The use of intensified timed-sequential induction and/or consolidation in all adult patients from our study might be a factor interacting with the prognostic impact of these mutations.
Given all the results reported to date, it remains quite hard to recommend how the detection of c-Kit mutations might interfere with treatment strategies in patients with CBF-AML. If one considers that these mutations are associated with a higher relapse incidence and a worse survival, intensified chemotherapy may be an option that has not been prospectively evaluated in CBF-AML patients specifically. Owing to the low rate of mutations reported in our study, we did not evaluate the place of allogeneic SCT performed in only 10% of patients (10/97 in first CR). Targeted TK inhibition using novel agents targeting c-Kit such as imatinib or dasatinib looks very attractive. Preliminary experiences with imatinib have already been reported. Unfortunately, it appears that TK inhibitors might abrogate the leukemic subclone carrying the class I mutation without exerting a significant anti-leukemic effect on the primary clone carrying the CBF gene rearrangement. 28 Treatment strategies combining TK inhibitors with standard chemotherapy for remission induction and consolidation, and/or immune system modulators for maintenance, might thus represent other options that could be prospectively tested in these high-risk patients. Finally, the place of allogeneic SCT remains elusive even in high-risk patients with high initial WBC and/or RTK mutations. In our previous French survey on t(8;21) AML patients, we did not observe any clinical benefit associated with intention to perform allogeneic SCT in first CR whatever WBC or WBC index was. 4 As a conclusion, one may recommend to further accumulate clinical and biological data while conducting specific therapeutic trials in CBF-AML patients. In addition to clinical parameters like WBC and RTK mutational status, baseline and post-treatment evaluation of fusion transcript levels using specific real-time quantitative PCR (RQ-PCR) should be recommended. Actually, very few reports have evaluated the prognostic impact of minimal residual disease (MRD) on the risk of further relapse in CBF-AML patients. [31] [32] [33] [34] [35] These reports often analyzed the value of MRD levels 'at any time of the follow-up' rather than at a predefined time (i.e. post-induction or postconsolidation) that would be more useful for treatment decisionmaking. However, the group from Munich has proposed to use a prognostic score combining transcription ratios at diagnosis and after 3-4 months of chemotherapy. 26 None of these studies has incorporated RTK mutation status and MRD results in a single multivariate prognostic analysis, such as it is not possible to determine which of these factors could be the most efficient to predict relapse. We are planning to do this work in the next adult CBF-2006 trial of the French AML Intergroup that will randomly evaluate the value of intensified timed-sequential induction in these patients. In this study which included only t(8;21) AML patients, mutations of the JM domain (exons 10 and 11) were also screened; 6 years RFS of patients with RTK and RAS mutations was 18 versus 60% in unmutated patients (P ¼ 0.03).
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In these studies, the whole c-kit gene was sequenced.
c
In this pediatric study, exons 9 and 11 mutations were also screened. In this pediatric study, exons 8, 9, 10, 11, 17 and 18 mutations were screened.
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